Across TCGA pan-cancer cohorts, MPZL1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MPZL1 data layer compared with 30 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MPZL1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MPZL1 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

HNSC, CCRCC, and GBM are the cancer types where MPZL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.758	0.482	.003	21	view →
CCRCC	OS	Median	II,III,IV	0.624	0.853	.017	9	view →
GBM	DFS	Median	All	0.280	0.455	.001	7	view →
LSCC	DFS	Median	II,III,IV	0.482	0.928	.019	6	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: MPZL1 tumor-vs-normal RNA expression · all MPZL1 data types